Concord Biotech, 543960, CONCORDBIO Share Price, Rating, Research, Analysis, Fundamental & Historical Data

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

18,629.53
50.13
1

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

18,628.73
0.60%
10.28

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

15.60
-
12.57

EBITDA CAGR (%)

10 Years
5 Years
3 Years

14.58
-
9.55

PAT CAGR (%)

10 Years
5 Years
3 Years

15.80
-
20.77

P:E (Median)

8 Years
5 Years
3 Years

P:BV (Average)

8 Years
5 Years
3 Years

EV:EBITDA (Average)

8 Years
5 Years
3 Years

Earnings Forecasts:

(Updated: 06-06-2025)

Description 2024 2025 2026 2027
Adj EPS 29.45 35.52 41.66 51.31
P/E Ratio 60.46 50.12 42.74 34.70
Revenue 998 1200 1398 1672
EBITDA 432 582 709
Net Income 308 372 436 536
ROA 19.2 21 22
P/B Ratio 12.21 8.54 7.09
ROE 21.88 20.85 20.9
FCFF 180 314 616
FCFF Yield 1.07 1.86 3.66
Net Debt -281 -668 -908
BVPS 145.8 208.43 251.13

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 25 Mar 24 Var% Dec 24 Dec 23 Var% Sep 24 Sep 23 Var% Jun 24 Jun 23 Var%
Net Sales 429.88 318.97 34.77% 244.22 240.80 1.42% 310.18 262.35 18.23% 215.80 194.83 10.76%
Expenses 239.46 184.68 29.66% 146.27 134.87 8.45% 173.50 143.16 21.19% 134.52 122.67 9.66%
EBITDA 190.42 134.29 41.80% 97.95 105.93 -7.53% 136.68 119.19 14.67% 81.28 72.15 12.65%
EBIDTM 44.30% 42.10% 40.11% 43.99% 44.06% 45.43% 37.66% 37.03%
Other Income 9.38 10.81 -13.23% 14.73 8.19 79.85% 10.03 8.13 23.37% 10.31 6.65 55.04%
Interest 0.10 0.46 -78.26% 0.10 0.50 -80.00% 0.10 0.84 -88.10% 0.24 0.75 -68.00%
Depreciation 14.62 13.72 6.56% 13.26 13.54 -2.07% 13.31 13.29 0.15% 13.18 13.04 1.07%
PBT 185.09 130.92 41.38% 99.32 100.09 -0.77% 133.29 113.18 17.77% 78.17 65.01 20.24%
Tax 43.16 33.70 28.07% 25.23 25.53 -1.18% 34.59 28.69 20.56% 19.93 16.54 20.50%
PAT 141.94 97.21 46.01% 74.09 74.55 -0.62% 98.70 84.49 16.82% 58.24 48.47 20.16%
PATM 33.02% 30.48% 30.34% 30.96% 31.82% 32.21% 26.99% 24.88%
EPS 13.57 9.29 46.07% 7.08 7.13 -0.70% 9.44 8.08 16.83% 5.57 4.63 20.30%

Description Mar 25 Mar 24 Var% Dec 24 Dec 23 Var% Sep 24 Sep 23 Var% Jun 24 Jun 23 Var%
Net Sales 429.88 318.97 34.77% 244.22 240.80 1.42% 310.18 262.35 18.23% 215.80 194.83 10.76%
Expenses 239.46 184.68 29.66% 146.27 134.87 8.45% 173.50 143.16 21.19% 134.52 122.67 9.66%
EBITDA 190.42 134.29 41.80% 97.95 105.93 -7.53% 136.68 119.19 14.67% 81.28 72.15 12.65%
EBIDTM 44.30% 42.10% 40.11% 43.99% 44.06% 45.43% 37.66% 37.03%
Other Income 9.38 10.81 -13.23% 14.73 8.19 79.85% 10.03 8.13 23.37% 10.31 6.65 55.04%
Interest 0.10 0.46 -78.26% 0.10 0.50 -80.00% 0.10 0.84 -88.10% 0.24 0.75 -68.00%
Depreciation 14.62 13.72 6.56% 13.26 13.54 -2.07% 13.31 13.29 0.15% 13.18 13.04 1.07%
PBT 185.09 130.92 41.38% 99.32 100.09 -0.77% 133.29 113.18 17.77% 78.17 65.01 20.24%
Tax 43.16 33.70 28.07% 25.23 25.53 -1.18% 34.59 28.69 20.56% 19.93 16.54 20.50%
PAT 141.94 97.21 46.01% 74.09 74.55 -0.62% 98.70 84.49 16.82% 58.24 48.47 20.16%
PATM 33.02% 30.48% 30.34% 30.96% 31.82% 32.21% 26.99% 24.88%
EPS 13.42 9.08 47.80% 7.26 7.41 -2.02% 9.15 7.74 18.22% 5.70 5.21 9.40%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated

Description TTM Mar 24 Mar 23 Mar 22 Mar 21 Mar 16 Mar 15 Mar 14 Mar 13 Mar 12 Mar 11
Net Sales 1,200.08 1,016.94 853.17 712.93 616.94 276.17 238.53 204.82 164.91 135.60 108.59 Net Sales Growth 18.01% 19.20% 19.67% 15.56% 123.39% 15.78% 16.46% 24.20% 21.62% 24.87% Cost Of Goods Sold 305.50 229.20 180.21 164.01 111.56 63.26 54.22 48.88 34.30 25.07 16.78 Gross Profit 894.58 787.74 672.96 548.92 505.37 212.91 184.31 155.93 130.61 110.53 91.81 GP Margin 74.54% 77.46% 78.88% 76.99% 81.92% 77.09% 77.27% 76.13% 79.20% 81.51% 84.55% Total Expenditure 693.75 584.75 504.59 439.01 289.01 140.63 127.67 119.26 88.75 69.85 49.51 Power & Fuel Cost - 104.97 97.65 71.64 39.86 26.89 28.90 29.45 25.71 21.27 15.15 % Of Sales - 10.32% 11.45% 10.05% 6.46% 9.74% 12.12% 14.38% 15.59% 15.69% 13.95% Employee Cost - 123.05 110.28 95.69 69.47 22.87 19.78 15.57 13.44 10.88 8.27 % Of Sales - 12.10% 12.93% 13.42% 11.26% 8.28% 8.29% 7.60% 8.15% 8.02% 7.62% Manufacturing Exp. - 31.23 38.44 32.45 21.97 12.42 12.32 12.35 8.45 7.00 4.99 % Of Sales - 3.07% 4.51% 4.55% 3.56% 4.50% 5.16% 6.03% 5.12% 5.16% 4.60% General & Admin Exp. - 54.73 45.72 31.09 22.52 8.72 6.53 6.42 3.54 2.59 1.81 % Of Sales - 5.38% 5.36% 4.36% 3.65% 3.16% 2.74% 3.13% 2.15% 1.91% 1.67% Selling & Distn. Exp. - 33.11 23.70 21.44 13.36 4.80 4.40 3.68 2.00 1.44 1.73 % Of Sales - 3.26% 2.78% 3.01% 2.17% 1.74% 1.84% 1.80% 1.21% 1.06% 1.59% Miscellaneous Exp. - 8.46 8.59 22.69 10.26 1.67 1.52 2.90 1.31 1.59 1.73 % Of Sales - 0.83% 1.01% 3.18% 1.66% 0.60% 0.64% 1.42% 0.79% 1.17% 0.71% EBITDA 506.33 432.19 348.58 273.92 327.93 135.54 110.86 85.56 76.16 65.75 59.08 EBITDA Margin 42.19% 42.50% 40.86% 38.42% 53.15% 49.08% 46.48% 41.77% 46.18% 48.49% 54.41% Other Income 44.45 33.78 35.31 23.42 13.81 4.58 5.51 2.83 5.31 2.58 3.81 Interest 0.54 3.18 9.80 6.13 1.05 0.32 0.82 0.70 0.30 0.41 0.35 Depreciation 54.37 53.59 54.03 50.05 27.52 10.46 9.67 11.43 10.14 8.97 7.26 PBT 495.87 409.19 320.05 241.16 313.17 129.34 105.88 76.25 71.04 58.95 55.28 Tax 122.91 104.46 81.93 62.59 77.83 42.09 35.63 21.83 21.65 17.17 16.00 Tax Rate 24.79% 25.53% 25.60% 25.95% 24.85% 32.54% 33.65% 28.63% 30.48% 29.13% 28.94% PAT 372.97 304.73 238.13 178.57 235.33 87.25 70.25 54.41 49.39 41.78 39.28 PAT before Minority Interest 372.97 304.73 238.13 178.57 235.33 87.25 70.25 54.41 49.39 41.78 39.28 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 31.08% 29.97% 27.91% 25.05% 38.14% 31.59% 29.45% 26.56% 29.95% 30.81% 36.17% PAT Growth 22.40% 27.97% 33.35% -24.12% 169.72% 24.20% 29.11% 10.16% 18.21% 6.36% EPS 35.66 29.13 22.77 17.07 22.50 8.34 6.72 5.20 4.72 3.99 3.76

Description TTM Mar 24 Mar 23 Mar 22 Mar 21
Net Sales 1,200.08 1,016.94 853.17 712.93 616.94 Net Sales Growth 18.01% 19.20% 19.67% 15.56% Cost Of Goods Sold 305.50 229.20 180.21 164.01 111.56 Gross Profit 894.58 787.74 672.96 548.92 505.38 GP Margin 74.54% 77.46% 78.88% 76.99% 81.92% Total Expenditure 693.75 584.75 504.59 439.01 289.01 Power & Fuel Cost - 104.97 97.65 71.64 39.86 % Of Sales - 10.32% 11.45% 10.05% 6.46% Employee Cost - 123.05 110.28 95.69 69.47 % Of Sales - 12.10% 12.93% 13.42% 11.26% Manufacturing Exp. - 31.23 38.44 32.48 21.97 % Of Sales - 3.07% 4.51% 4.56% 3.56% General & Admin Exp. - 54.73 45.72 31.09 22.52 % Of Sales - 5.38% 5.36% 4.36% 3.65% Selling & Distn. Exp. - 33.11 23.70 21.44 13.36 % Of Sales - 3.26% 2.78% 3.01% 2.17% Miscellaneous Exp. - 8.46 8.59 22.66 10.26 % Of Sales - 0.83% 1.01% 3.18% 1.66% EBITDA 506.33 432.19 348.58 273.92 327.93 EBITDA Margin 42.19% 42.50% 40.86% 38.42% 53.15% Other Income 44.45 33.78 35.31 23.42 13.81 Interest 0.54 3.18 9.80 6.13 1.05 Depreciation 54.37 53.59 54.03 50.05 27.52 PBT 495.87 409.19 320.05 241.16 313.17 Tax 122.91 104.46 81.93 62.59 77.83 Tax Rate 24.79% 25.53% 25.60% 25.95% 24.85% PAT 372.97 308.10 240.09 174.93 235.34 PAT before Minority Interest 372.97 308.10 240.09 174.93 235.34 Minority Interest 0.00 0.00 0.00 0.00 0.00 PAT Margin 31.08% 30.30% 28.14% 24.54% 38.15% PAT Growth 22.40% 28.33% 37.25% -25.67% EPS 35.66 29.46 22.95 16.72 22.50

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 14 Mar 13 Mar 12 Mar 11 Mar 10 Mar 09
Shareholder's Funds 1,525.25 1,291.98 1,107.16 999.67 226.47 185.52 146.30 111.20 77.28 64.87 Share Capital 10.46 10.46 9.51 9.51 9.21 4.60 4.60 4.60 2.30 2.53 Total Reserves 1,514.79 1,281.52 1,097.65 990.16 217.26 180.92 141.69 106.60 74.98 62.34 Non-Current Liabilities 31.91 32.13 54.40 77.43 10.53 9.03 7.94 7.97 5.90 10.01 Secured Loans 0.00 6.24 31.25 56.25 0.00 0.00 0.00 0.00 2.27 7.23 Unsecured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Provisions 1.96 2.30 1.87 2.10 0.27 0.28 0.55 0.78 0.00 0.00 Current Liabilities 142.16 190.53 340.97 235.93 37.96 27.55 24.26 21.01 16.30 16.27 Trade Payables 94.44 93.80 83.11 46.40 15.38 9.03 6.95 5.22 8.35 4.10 Other Current Liabilities 38.32 60.26 62.70 53.58 3.93 2.28 3.58 6.45 1.54 1.22 Short Term Borrowings 0.00 0.00 4.34 5.10 4.97 3.62 6.59 3.86 0.00 0.00 Short Term Provisions 9.40 36.47 190.82 130.85 13.68 12.62 7.15 5.47 6.41 10.95 Total Liabilities 1,699.32 1,514.64 1,502.53 1,313.03 274.96 222.10 178.50 140.18 99.48 91.15 Net Block 575.32 592.98 572.98 546.22 98.73 81.62 69.48 63.94 40.42 32.99 Gross Block 828.31 792.80 718.85 644.29 161.05 132.77 110.61 96.21 65.56 52.98 Accumulated Depreciation 253.00 199.81 145.87 98.08 62.31 51.15 41.14 32.28 25.14 19.99 Non Current Assets 803.08 786.95 869.87 705.89 113.02 88.35 87.86 73.36 52.46 39.43 Capital Work in Progress 211.48 172.70 74.16 17.95 8.02 3.97 14.42 7.00 12.04 6.44 Non Current Investment 0.67 0.79 0.92 0.67 0.56 0.56 0.00 0.00 0.00 0.00 Long Term Loans & Adv. 12.81 11.61 220.99 140.61 5.72 2.00 3.77 2.41 0.00 0.00 Other Non Current Assets 2.81 8.87 0.82 0.45 0.00 0.21 0.19 0.00 0.00 0.00 Current Assets 896.23 727.70 632.67 607.15 161.94 133.75 90.64 66.81 47.03 51.72 Current Investments 243.70 136.93 73.47 140.99 0.00 2.00 2.02 0.00 3.01 12.03 Inventories 207.95 212.31 195.12 153.61 39.41 34.36 23.66 18.75 14.04 14.99 Sundry Debtors 349.61 273.76 232.17 177.52 100.35 85.43 54.83 30.17 23.82 10.91 Cash & Bank 47.02 43.45 88.93 60.82 2.67 1.53 1.04 12.22 0.61 0.23 Other Current Assets 47.94 45.57 32.53 40.37 19.50 10.42 9.09 5.67 5.54 13.55 Short Term Loans & Adv. 21.12 15.68 10.44 33.85 10.58 2.76 2.83 2.07 5.34 13.41 Net Current Assets 754.08 537.17 291.70 371.22 123.98 106.20 66.38 45.81 30.73 35.45 Total Assets 1,699.31 1,514.65 1,502.54 1,313.04 274.96 222.10 178.50 140.17 99.49 91.15

Description Mar 24 Mar 23 Mar 22 Mar 21
Shareholder's Funds 1,526.65 1,290.00 1,103.22 999.37 Share Capital 10.46 10.46 9.51 9.51 Total Reserves 1,516.18 1,279.54 1,093.71 989.86 Non-Current Liabilities 31.91 32.13 54.40 77.43 Secured Loans 0.00 6.24 31.25 56.25 Unsecured Loans 0.00 0.00 0.00 0.00 Long Term Provisions 1.96 2.30 1.87 2.10 Current Liabilities 142.16 191.84 344.24 235.93 Trade Payables 94.44 93.80 83.11 46.40 Other Current Liabilities 38.32 61.57 65.98 53.58 Short Term Borrowings 0.00 0.00 4.34 5.10 Short Term Provisions 9.40 36.47 190.82 130.85 Total Liabilities 1,700.72 1,513.97 1,501.86 1,312.73 Net Block 575.32 592.98 572.98 546.22 Gross Block 828.31 792.80 718.85 645.33 Accumulated Depreciation 253.00 199.81 145.87 99.11 Non Current Assets 804.48 786.28 869.20 705.59 Capital Work in Progress 211.48 172.70 74.16 17.95 Non Current Investment 2.06 0.12 0.26 0.37 Long Term Loans & Adv. 12.81 11.61 220.99 140.61 Other Non Current Assets 2.81 8.87 0.82 0.45 Current Assets 896.23 727.70 632.67 607.15 Current Investments 243.70 136.93 73.47 140.99 Inventories 207.95 212.31 195.12 153.61 Sundry Debtors 349.61 273.76 232.17 177.52 Cash & Bank 47.02 43.45 88.93 60.82 Other Current Assets 47.94 45.57 32.53 40.37 Short Term Loans & Adv. 21.12 15.68 10.44 33.85 Net Current Assets 754.08 535.86 288.42 371.22 Total Assets 1,700.71 1,513.98 1,501.87 1,312.74

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 14 Mar 13 Mar 12 Mar 11 Mar 10 Mar 09
Cash From Operating Activity 265.47 246.00 207.47 166.81 39.81 21.53 16.14 36.04 34.70 18.96 PBT 409.19 320.05 241.16 313.17 76.25 71.04 58.95 55.28 55.92 14.21 Adjustment 40.80 48.51 49.16 17.59 15.07 8.58 8.18 7.52 5.26 5.08 Changes in Working Capital -81.18 -52.29 -22.06 -88.77 -24.01 -41.68 -33.34 -11.66 -9.66 3.93 Cash after chg. in Working capital 368.82 316.28 268.26 241.99 67.30 37.94 33.79 51.14 51.53 23.22 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -103.35 -70.28 -60.78 -75.18 -27.49 -16.41 -17.64 -15.10 -16.82 -4.39 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.13 Cash From Investing Activity -154.61 -157.95 -111.79 -195.20 -31.41 -10.85 -21.79 -22.40 -8.71 -20.05 Net Fixed Assets -74.29 -172.49 -130.77 -493.17 -32.33 -11.71 -21.82 -25.61 -18.18 -8.21 Net Investments -106.65 -63.33 67.27 -141.10 2.00 -0.54 -2.02 3.01 9.02 -12.03 Others 26.33 77.87 -48.29 439.07 -1.08 1.40 2.05 0.20 0.45 0.19 Cash from Financing Activity -99.21 -85.22 -100.16 31.12 -9.32 -9.82 -3.83 -1.98 -25.61 0.14 Net Cash Inflow / Outflow 11.64 2.83 -4.48 2.74 -0.91 0.85 -9.48 11.66 0.38 -0.95 Opening Cash & Equivalents 3.50 0.67 5.14 2.41 3.52 2.66 12.14 0.57 0.23 1.18 Closing Cash & Equivalent 15.14 3.50 0.67 5.14 2.60 3.52 2.66 12.22 0.61 0.23

Description Mar 24 Mar 23 Mar 22 Mar 21
Cash From Operating Activity 265.47 246.00 207.47 166.82 PBT 412.56 322.01 237.52 312.72 Adjustment 37.43 46.55 52.80 18.04 Changes in Working Capital -81.18 -52.29 -22.05 -88.76 Cash after chg. in Working capital 368.82 316.28 268.26 241.99 Interest Paid 0.00 0.00 0.00 0.00 Tax Paid -103.35 -70.28 -60.78 -75.18 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 Cash From Investing Activity -154.61 -157.95 -111.79 -195.21 Net Fixed Assets -74.29 -172.49 -130.77 Net Investments -106.65 -63.33 67.27 Others 26.33 77.87 -48.29 Cash from Financing Activity -99.21 -85.22 -100.16 31.12 Net Cash Inflow / Outflow 11.64 2.83 -4.48 2.74 Opening Cash & Equivalents 3.50 0.67 5.14 2.41 Closing Cash & Equivalent 15.14 3.50 0.67 5.14

Financial Ratios

Standalone /

Consolidated

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 14 Mar 13 Mar 12 Mar 11 Mar 10 Mar 09
Book Value (Rs.) 145.80 123.50 105.83 95.56 246.02 403.07 317.85 241.60 335.83 256.06 ROA 18.96% 15.78% 12.68% 20.89% 21.89% 24.66% 26.22% 32.78% 38.53% 11.59% ROE 21.63% 19.85% 16.95% 26.60% 26.42% 29.77% 32.45% 41.68% 51.67% 16.10% ROCE 28.89% 26.48% 21.94% 33.00% 36.59% 41.71% 44.18% 56.95% 74.38% 22.42% Fixed Asset Turnover 1.25 1.13 1.05 1.29 1.44 1.42 1.35 1.39 1.79 1.06 Receivable days 111.87 108.22 104.87 106.80 160.03 148.42 111.49 87.54 59.62 67.04 Inventory Days 75.42 87.15 89.27 78.34 63.55 61.40 55.63 53.17 49.83 113.67 Payable days 149.88 179.16 144.10 192.42 36.90 30.92 29.60 45.56 48.65 29.49 Cash Conversion Cycle 37.41 16.22 50.04 -7.28 186.68 178.90 137.51 95.15 60.81 151.22 Total Debt/Equity 0.00 0.02 0.05 0.09 0.02 0.02 0.05 0.04 0.03 0.11 Interest Cover 129.52 33.65 40.31 300.20 109.58 238.74 144.64 156.79 119.05 19.33

Description Mar 24 Mar 23 Mar 22 Mar 21
Book Value (Rs.) 145.93 123.31 105.45 95.52 ROA 19.17% 15.92% 12.43% 20.89% ROE 21.88% 20.06% 16.64% 26.60% ROCE 29.13% 26.70% 21.66% 33.01% Fixed Asset Turnover 1.25 1.13 1.05 1.29 Receivable days 111.87 108.22 104.87 106.80 Inventory Days 75.42 87.15 89.27 78.34 Payable days 149.88 179.16 144.10 192.42 Cash Conversion Cycle 37.41 16.22 50.04 -7.28 Total Debt/Equity 0.00 0.02 0.05 0.09 Interest Cover 130.57 33.85 39.72 300.11

Top Investors:

aryavir jhunjhunwala discretionary trust

nishtha jhunjhunwaladiscretionary trust

aryaman jhunjhunwaladiscretionary trust

government pension fund global

1575773 ontario inc

amal parikh

axis max life insurance limited a/c reversionary bonus participating - equity

tata aia life insurance co ltd unit linked multi cap fund

ravindra raichand dharamshi

chanakya corporate services private limited

Annual Reports:

News Update:

Concord Biotech gets EIR from USFDA for API facility at Dholka
24th Jun 2025, 15:43 PM

The said inspection was conducted from April 28, 2025 till May 02, 2025
Read More
Concord Biotech gets final approval from USFDA for marketing Teriflunomide Tablets
9th Apr 2025, 09:02 AM

The approval reinforces company’s capability in successfully developing and commercializing a differentiated product portfolio for the U.S. market
Read More
Concord Biotech commences production of injectable at Valthera facility
25th Mar 2025, 14:30 PM

This advanced facility has been designed and constructed to adhere to stringent international standards
Read More

Concord Biotech Ltd.

Pharmaceuticals & Drugs

BSE: 543960 | NSE: CONCORDBIO

Stock Summary

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Standalone Figures in Rs. Crores /

Results Balance Sheet

Standalone Figures in Rs. Crores /

Cash Flow

Standalone Figures in Rs. Crores /

Financial Ratios

Standalone /

Top Investors:

Annual Reports:

News Update:

Concord Biotech Ltd.

Pharmaceuticals & Drugs

BSE: 543960 | NSE: CONCORDBIO

Stock Summary

Shareholding Pattern

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Standalone Figures in Rs. Crores /

Results Balance Sheet

Standalone Figures in Rs. Crores /

Cash Flow

Standalone Figures in Rs. Crores /

Financial Ratios

Standalone /

Top Investors:

Annual Reports:

News Update: